DAFTAR PUSTAKA

1. Igarashi P, Somlo S. Polycystic Kidney Disease. J Am Soc Nephrol.

2007; 18: 1371-1373.

2. Harvorson CL, Bremmer MS, Jacobs SC. Polycystic Kidney Disease :

Inheritance, Pathophysiology, Prognosis and Treatment. Int J Nephrol
Renovasc Dis. 2010; 3: 69-83.

3. Grantham JJ, Torres VE, Chapman AB, Woodford LMG, Bae KT, King
Jr BF, et al. Volume Progression in Polycystic Kidney Disease. N Engl J
Med. 2006; 354: 2122-2130.

4. Wilson PD. Mechanism of Disease Polycystic Kidney Disease. N Engl

J Med. 2004; 350: 151-164.

5. Goldman L, Schafer AI. Cystic Kidney Diseases. In : Goldman L,

Schafer AI, Arend WP, Armitage JO, Clemmons DR, Drazen JM, et al.,
(editors). Goldmans Cecil Medicine. 24th ed. Philadelphia: Elsevier
Saunders; 2012. p. 794-800.

6. Grantham JJ. Cystic Diseases of The Kidney. In : Taal MW, Chertow

GM, Marsden PA, Skorecki K, Yu ASL, Brenner BM, (editors). Brenner
and Rectors The Kidney. 9th ed. Philadelphia: Elsevier Saunders; 2012.
p. 1626-1667.

7. Harris PC, Torres VE. Polycystic Kidney Disease. Annu Rev Med.
2009; 60: 321-337.

8. National Institute of Health. Polycystic Kidney Disease. New York:

National Institutes of Health; 2007;50 : 110-120.

9. Grantham JJ. Autosomal Dominant Poycystic Kidney Disease. N Engl J

Med. 2008; 359: 1477-1485.

10. Elhassan E, Masoumi A, Schrier RW. Progress on Autosomal Dominant

Polycystic Kidney Disease. Arab J Nephrol Transplant. 2009; 2: 27-44.

11. Pirson Y, Chauveau D, Devuyst O. Cystic Diseases. In : Davison AM,

Cameron JS, Grunfeld JP, Ponticelli C, Ritz E, Winearls CG, et al.,
(editors). Oxford Textbook of Clinical Nephrology. 3rd ed. Oxford:
Oxford University Press; 2005. p. 2035-2321.

12. Neumann HPH, Jilg C, Bacher J, Nabulsi Z, Malinoc A, Hummel B, et

al. Epidemiology of Autosomal Dominant Polycystic Kidney Disease :

31
 an In-Depth Clinical Study for South Western Germany. Nephrol Dial
Transplant. 2013; 28: 1472-1487.

13. Bastos AP, Onuchic LF. Molecular and Cellular Pathogenesis of

Autosomal Dominant Polycystis Kidney Disease. Braz J Med Biol Res.
2011; 44: 606-617.

14. Harris PC. Polycystic Disease of The Kidney. Encycl Life Sci. 2001; 1:
1-8.

15. Braun WE. Autosomal Dominant Polycystic Kidney Disease :

Emerging Concept of Pathogenesis and New Treatments. Clev Clin J
Med. 2009; 76: 97-107.

16. Torres VE, Harris PC. Polycystic Kidney Disease : Genes, Proteins,
Animal Models, Disease Mechanism and Therapeutic Opportunities. J
Intern Med. 2007; 261: 17-31.

17. Badani KK, Hemal AK, Menon M. Autosomal Dominant Polycystic

Kidney Disease and Pain A Review of The Disease From Aetiology,
Evaluation, Past Surgical Treatment Options to Current Practice. J
Postgrad Med. 2004;50 : 222-225.

18. Ecder T, Fick-Brosnahan GM., Schrier RW. Polycystic Kidney Disease.

In : Schrier RW, editor. Diseases of The Kidney and Urinary Tract. 8 th
ed. Philadelphia: Lippincott William and Wilkins; 2007.p. 502-539.

19. RussellRT,PinsonCW.Surgicalmanagementofpolycysticliverdisease.
WorldJGastroenterol2007;13:50525059.

20. VanKeimpemaL,RuurdaJP,ErnstMF,vanGeffenHJ,DrenthJP.
Laparoscopicfenestrationoflivercystsinpolycysticliverdiseaseresultsina
medianvolumereductionof12.5%.JGastrointestSurg2008;12:477482.

21. MartinIJ,McKinleyAJ,CurrieEJ,HolmesP,GardenOJ.Tailoringthe
managementofnonparasiticlivercysts.AnnSurg1998;228:167172.

22. PayatakesAH,KakkosSK,SolomouEG,TepetesKN,KaraviasDD.Surgical
treatmentofnonparasitichepaticcysts:reportof12cases.EurJSurg
1999;165:11541158.

23. ArmitageNC,BlumgartLH.Partialresectionandfenestrationinthetreatment
ofpolycysticliverdisease.BrJSurg1984;71:242244.

24. SchindlMJ,RedheadDN,FearonKC,GardenOJ,WigmoreSJ.Thevalueof
residuallivervolumeasapredictorofhepaticdysfunctionandinfectionafter
majorliverresection.Gut2005;54:289296.

25. RasmussenA,DaviesHF,JamiesonNV,EvansDB,CalneRY.Combined

31
 transplantationofliverandkidneyfromthesamedonorprotectsthekidney
fromrejectionandimproveskidneygraftsurvival.Transplantation
1995;59:919921.

26. ShakedA,ThompsonM,WilkinsonAH,NuesseB,elKhouryGF,Rosenthal
JT,etal.Theroleofcombinedliver/kidneytransplantationinendstage
hepatorenaldisease.AmSurg1993;59:606609.

27. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ,
Higashihara E, et al. Tolvaptan in Patients with Autosomal Dominant
Polycystic Kidney Disease. N Engl J Med. 2012; 367: 2407-2418.

28. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, et al.
Sirolimus and Kidney Growth in Autosomal Dominant Polycystic
Kidney Disease. N Eng J Med. 2010; 363: 820-829.

29. Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, Sommerer C,

et al. Everolimus in Patient with Autosomal Dominant Polycystic
Kidney Disease. N Engl J Med. 2010; 363: 830-840.

30. Aguiari G, Catizone L, Senno LD. Multidrug Therapy for Polycystic

Kidney Disease : A Review and Perspective. Am J Nephrol. 2013; 37:
175-182.

31. Perkumpulan Nefrologi Indonesia. 4th Report of Indonesian Renal

Registry. Jakarta: Perkumpulan Nefrologi Indonesia; 2011.

32. Everson GT, Taylor MR, Doctor RB. Polycystic disease of the liver.
HEPATOLOGY 2004;40:774-782

31
31